Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
- 14 June 2001
- journal article
- clinical trial
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 39 (1-2) , 181-194
- https://doi.org/10.1016/s1040-8428(01)00107-x
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2000
- Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin’s LymphomasJournal of Clinical Oncology, 2000
- Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+B-Cell Non-Hodgkin's LymphomaJournal of Clinical Oncology, 1999
- Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphomaAnnals of Oncology, 1998
- Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.Journal of Clinical Oncology, 1996
- Radioactive decay data tablesPublished by Office of Scientific and Technical Information (OSTI) ,1981